Clinical Trials Logo

MRD clinical trials

View clinical trials related to MRD.

Filter by:
  • None
  • Page 1

NCT ID: NCT06409702 Not yet recruiting - Multiple Myeloma Clinical Trials

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Start date: May 2024
Phase:
Study type: Observational

The goal of this study is to evaluate sustained MRD negativity for one year in DKRD induction & consolidation therapy +/- ASCT in newly diagnosed high-risk multiple myeloma patients. It aims to evaluate the efficacy and safety of the combination regimen of Daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone (DKRD) +/- ASCT for the treatment of patients with newly diagnosed high-risk multiple myeloma. Participants will receive bortezomib based induction therapy for one cycle, and then DKRD induction for 3 cycles(+ASCT), DKRD consolidation for 2-4 cycles, and DKR maintenance treatment(adjusted according to MRD negativity after consolidation therapy)

NCT ID: NCT05736978 Recruiting - AML Clinical Trials

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

AVS
Start date: March 31, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia based on MRD results on day 14 of the first cycle.

NCT ID: NCT05536505 Recruiting - MRD Clinical Trials

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

Start date: September 13, 2022
Phase: Phase 2
Study type: Interventional

A prospective, multicenter clinical study designed to explore the efficacy of postoperative adjuvant EGFR-TKIs therapy based on MRD status in patients with stage IB-IIIB EGFR-mutant non-squamous non-small cell lung cancer (non-squamous NSCLC). Primary endpoints include 3-year Disease-Free Survival rate (3y-DFS) and median disease-free survival (mDFS).

NCT ID: NCT03971305 Recruiting - Pediatric Cancer Clinical Trials

A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL

Start date: May 5, 2017
Phase:
Study type: Observational [Patient Registry]

With the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-Hodgkin lymphoma (NHL) in children. In recent years, the criteria for clinical staging and efficacy evaluation of NHL in children have been updated. Studies in Germany and the United States have shown that pathological types of systemic anaplastic large cell lymphoma (ALCL) in children and adolescents, minimal disseminated disease (MDD) in peripheral blood or bone marrow and minimal residual disease (MRD) are significantly associated with prognosis, suggesting that these factors need to be combined in risk stratification of ALCL patients. Recent studies have also suggested that PET/CT is helpful in evaluating residual lesions in patients with lymphoma after chemotherapy. In order to keep pace with the times in the diagnosis, clinical staging, risk stratification, efficacy evaluation and treatment of NHL in children. We adjusted the original NHL-BFM-90/95 regimen, mainly in the aspects of clinical staging, efficacy evaluation, risk stratification and treatment regimen,etc.

NCT ID: NCT03620955 Recruiting - MRD Clinical Trials

Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

Start date: August 10, 2018
Phase:
Study type: Observational

Risk-stratified therapy based on molecular and cytogenetic for acute myeloid leukemia (AML) is well accepted and benefits patients' survival. However, neither every patient with low risk factors obtains better survival, nor all high risk patients experience worse outcome. Lots of data have shown that the early treatment response presenting as minimal residual disease (MRD) has an important role in prognostic prediction. In this study, we perform risk stratification based on not only Cytogenetic and Molecular characteristic, but also MRD after three courses of chemo therapy in AML cohort. Patients with MRD positive would be moved to a higher risk class. And then the risk-stratified therapy should be considered according to the new risk stratification.

NCT ID: NCT02872662 Recruiting - MDS Clinical Trials

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

Start date: August 2016
Phase: N/A
Study type: Observational

This study aims to develop highly sensitive methods for early detection of relapse based on the patients unique mutations. Initially, a mutational screen is being performed. Primers directed against these mutations will be constructed and presence of mutations will be followed in bone marrow and blood frequently after transplantation.